French study aims to perfect leukemia treatment for kids
NCT ID NCT02716233
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This French study looks at 2,044 children and teens with acute lymphoblastic leukemia (ALL) to find the best way to give the drug pegaspargase. Some patients get one large dose, while others get two smaller doses. The goal is to see which schedule works better and causes fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pegaspargase (ONCASPAR)
What this could lead to
If successful, this could establish a safer and more effective dosing schedule for pegaspargase, improving outcomes for children with ALL.
What could go wrong
This is an observational cohort study, not a randomized controlled trial for all groups, so results may be less definitive. The drug can cause serious side effects like pancreatitis and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU
Besançon, 25030, France
-
CHU
Amiens, 80054, France
-
CHU
Angers, 49033, France
-
CHU
Bordeaux, 33076, France
-
CHU
Brest, 29609, France
-
CHU
Caen, 14033, France
-
CHU
Clermont-Ferrand, 63003, France
-
CHU
Dijon, 21079, France
-
CHU
Grenoble, 38043, France
-
CHU
Lille, 59037, France
-
CHU
Limoges, 87042, France
-
CHU
Marseille, 13385, France
-
CHU
Montpellier, 34295, France
-
CHU
Nancy, 54511, France
-
CHU
Nantes, 44093, France
-
CHU
Nice, 06200, France
-
CHU
Poitiers, 86000, France
-
CHU
Reims, 51100, France
-
CHU
Rennes, 35203, France
-
CHU
Rouen, 76031, France
-
CHU
Saint-Etienne, 42270, France
-
CHU
Strasbourg, 67098, France
-
CHU
Toulouse, 31059, France
-
CHU
Tours, 37044, France
-
CHU Armand Trousseau
Paris, 75012, France
-
CHU Robert Debré
Paris, 75019, France
-
CHU Saint Louis
Paris, 75010, France
-
Chu-Ihope
Lyon, 69373, France